• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vera Therapeutics, Inc. - Class A Common Stock (NQ:VERA)

29.05 UNCHANGED
Delayed Quote Updated: 4:00 PM EDT, Oct 22, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 20
Open 29.05
Bid (Size) 29.05 (100)
Ask (Size) 31.70 (200)
Prev. Close 29.05
Today's Range 29.05 - 29.05
52wk Range 23.05 - 56.05
Shares Outstanding 44,261,109
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Vera Therapeutics' TRUTAKNA Delivers Strong Phase III IgA Nephropathy Results ↗
October 22, 2026
Vera Therapeutics (NASDAQ:VERA) reported final efficacy results from its Phase III ORIGIN trial evaluating atacicept, marketed as TRUTAKNA, in adults with IgA nephropathy. The company presented the... 
Via MarketBeat
News headline image
Vera Therapeutics Announces Positive ORIGIN 3 Final Efficacy Analysis of TRUTAKNA™ (atacicept-vymj) in IgA Nephropathy Presented at ASN Kidney Week 2026 and Published in the New England Journal of Medicine
October 22, 2026
From Vera Therapeutics
Via GlobeNewswire

Performance

52-Week Range 48.2% below 52-week high
29.05
23.0552W Low 56.0552W High
1 Week 8.8% below 1-week high
27.501W Low 31.841W High

Vera Therapeutics, Inc. - Class A Common Stock (VERA) traded between $23.05 and $56.05 over the past 52 weeks and last traded at $29.05, 48.2% below its 52-week high. Over the past week it ranged between $27.50 and $31.84.

Past 12 Months
+4.2%
-19.9%
-20.1%
-24.3%
-40.3%
-3.0%
1W +$1.17
1M -$7.21
3M -$7.30
6M -$9.34
YTD -$19.57
1Y -$0.89

VERA was -3.0% over the past year, -24.3% over six months, -40.3% year to date, +4.2% in the last week.

12 Months vs Market
VERA
-3.0%
DIA
+13.3%
SPY
+14.4%
QQQ
+16.3%
IWM
+13.7%

Over the past 12 months VERA returned -3.0% versus DIA (Dow) +13.3%, SPY (S&P 500) +14.4%, QQQ (Nasdaq 100) +16.3% and IWM (Russell 2000) +13.7%.

Volume & Liquidity 0.00× 3-mo avg
Today 20 3-mo avg 2.2M
1W
1.7M
1M
1.8M
3M
2.2M
6M
1.9M
YTD
1.6M
1Y
1.6M

VERA most recently traded 20 shares against a 3-month average daily volume of 2.2M.

More News

Read More
News headline image
Vera Therapeutics to Host ASN Kidney Week Investor Webcast and Third Quarter 2026 Financial Results Conference Webcast
October 20, 2026
From Vera Therapeutics
Via GlobeNewswire
News headline image
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 02, 2026
From Vera Therapeutics
Via GlobeNewswire
News headline image
Vera Therapeutics Announces ORIGIN 3 Final Efficacy Analysis of TRUTAKNA™ (atacicept-vymj) in IgA Nephropathy Will be A Featured Late-breaking Oral Presentation at the Opening Plenary Session of ASN Kidney Week 2026
October 02, 2026
From Vera Therapeutics
Via GlobeNewswire
What's going on in today's pre-market session ↗
September 15, 2026
Via Chartmill
News headline image
Vera Therapeutics Announces TRUTAKNA™ (atacicept-vymj) Stabilized eGFR and Prevented Kidney Disease Progression Through Two Years in ORIGIN 3 Final Efficacy Analysis in IgA Nephropathy
September 15, 2026
From Vera Therapeutics
Via GlobeNewswire
News headline image
Vera Therapeutics to Participate at Upcoming Investor Conferences
September 01, 2026
From Vera Therapeutics
Via GlobeNewswire
News headline image
Vera Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results
August 10, 2026
From Vera Therapeutics
Via GlobeNewswire
News headline image
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 07, 2026
From Vera Therapeutics
Via GlobeNewswire
News headline image
Vera Therapeutics Wins FDA Approval for TRUTAKNA in IgA Nephropathy, Sets Launch ↗
July 11, 2026
Via MarketBeat
News headline image
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 10, 2026
From Vera Therapeutics
Via GlobeNewswire
News headline image
Vera Therapeutics Announces Appointment of Nancy Boman as Chief Regulatory Officer and Planned Retirement of William Turner
July 09, 2026
From Vera Therapeutics
Via GlobeNewswire
News headline image
Vera Therapeutics Receives FDA Accelerated Approval for TRUTAKNA™ for Adult Patients with Primary IgA Nephropathy
July 07, 2026
From Vera Therapeutics
Via GlobeNewswire
News headline image
3 Biotech Firms With Major Potential Catalysts in the Coming Months ↗
June 21, 2026
Via MarketBeat
Topics Intellectual Property
News headline image
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 05, 2026
From Vera Therapeutics
Via GlobeNewswire
News headline image
Vera Therapeutics Announces Alignment with U.S. FDA on Earlier ORIGIN Phase 3 Analysis to Support Potential Full Approval for Atacicept in Adults with IgA Nephropathy
June 02, 2026
From Vera Therapeutics
Via GlobeNewswire
News headline image
Investment Firm Closes Out Entire $18.1 Million Position in Biotech Stock, According to Latest SEC Filing ↗
May 26, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 08, 2026
From Vera Therapeutics
Via GlobeNewswire
News headline image
Vera Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results
May 07, 2026
From Vera Therapeutics
Via GlobeNewswire
News headline image
Vera Therapeutics to Participate in the Bank of America Securities 2026 Health Care Conference
May 04, 2026
From Vera Therapeutics
Via GlobeNewswire
News headline image
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 10, 2026
From Vera Therapeutics
Via GlobeNewswire
News headline image
Biogen's $5.6 Billion Acquisition of Apellis: A Strategic Pivot into Rare Kidney Diseases
March 31, 2026
Via MarketMinute
News headline image
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 27, 2026
From Vera Therapeutics
Via GlobeNewswire
News headline image
Vera Therapeutics Appoints Jane Wright-Mitchell as Chief Legal Officer
March 25, 2026
From Vera Therapeutics
Via GlobeNewswire

Frequently Asked Questions

Is Vera Therapeutics, Inc. - Class A Common Stock publicly traded?
Yes, Vera Therapeutics, Inc. - Class A Common Stock is publicly traded.
What exchange does Vera Therapeutics, Inc. - Class A Common Stock trade on?
Vera Therapeutics, Inc. - Class A Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Vera Therapeutics, Inc. - Class A Common Stock?
The ticker symbol for Vera Therapeutics, Inc. - Class A Common Stock is VERA on the Nasdaq Stock Market
What is the current price of Vera Therapeutics, Inc. - Class A Common Stock?
The current price of Vera Therapeutics, Inc. - Class A Common Stock is 29.05
When was Vera Therapeutics, Inc. - Class A Common Stock last traded?
The last trade of Vera Therapeutics, Inc. - Class A Common Stock was at 10/22/26 04:00 PM ET
What is the market capitalization of Vera Therapeutics, Inc. - Class A Common Stock?
The market capitalization of Vera Therapeutics, Inc. - Class A Common Stock is 1.29B
How many shares of Vera Therapeutics, Inc. - Class A Common Stock are outstanding?
Vera Therapeutics, Inc. - Class A Common Stock has 1B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap